GLP-1 in 2026: The complete guide to semaglutide, tirzepatide, and the cost lanes between $80 personal-import to $1,800 retail per month.

You're 45. You've gained 30 pounds since you turned 40. You walk past a Wegovy ad every other day. Your insurance / NHS / Medicare said no. Your cousin lost 40 pounds in 9 months on something a telehealth clinic shipped her. Reddit says $80/month from India. Your doctor / GP said "nutrition consult."

You don't know who's lying.

Probably nobody. They're all describing real lanes that work for different people at different costs in different countries. The US, UK, Australia, and EU each have their own access rails — Wegovy at $1,800 retail in the US, NHS rationing it to BMI ≥35 with comorbidity in England, the TGA personal-importation 3-month rule in Australia, EMA-approved supply running through European pharmacies — and each rail is selling you only its own version of the story.

This is the version that walks all the lanes — the molecule, the trials, the pricing, the side effects, the stopping question, and where personal-import actually fits across the four major Anglo-EU jurisdictions. About 20 minutes to read. The decision tree at the end is the part that matters.

Quick navigation: Section 3 is the cost lane table. Section 7-8 is the personal-import legal framework (US 90-day, UK MHRA, AU TGA, EU). Section 9 is the decision tree. If you just need cost lanes and what to do this week, jump to Section 3 and Section 9.

1. The class is real. Be careful what you compare it to.

Before 2017, weight-loss drugs were a graveyard.

Phen-fen pulled (1997). Sibutramine pulled (2010). Lorcaserin pulled (2020). Orlistat (Xenical/Alli) — survives, ~5% weight loss with diarrhea side effect. Phentermine — short-term only, amphetamine class. Naltrexone-bupropion (Contrave) — ~5% loss. Liraglutide (Saxenda, the daily-injection GLP-1 ancestor) — ~5-7% loss.

Then semaglutide weekly injection cleared FDA in 2021. The STEP-1 trial (Wilding et al., NEJM 2021;384:989) ran 1,961 adults at 2.4mg weekly for 68 weeks. Mean weight loss: -14.9% of body weight vs. -2.4% on placebo. ~85% of participants lost ≥5%. ~50% lost ≥15%.

Then tirzepatide (Mounjaro/Zepbound) cleared in 2022. SURMOUNT-1 (Jastreboff et al., NEJM 2022;387:205) ran 2,539 adults at 15mg weekly for 72 weeks. Mean weight loss at the 15mg dose: -20.9%.

For context: a 220-pound man losing 20% loses 44 pounds. That's bariatric-surgery-adjacent without the surgery.

This is the first weight-loss drug class that does what the marketing actually claims. Lifestyle interventions (the structured, supervised, expensive kind — not "eat less move more") get you ~5% over a year and most people regain it. GLP-1s get you 3-4× that, and the regain only kicks in if you stop the drug.

The class is the real thing. The arguments are about who pays for it, what dose, which molecule, and for how long.

2. The molecules, in plain terms

Five drugs are in the GLP-1 / GLP-1-adjacent category as of April 2026. They are not interchangeable. Here's what each one is.

Semaglutide

• Brand names: Wegovy (weight loss indication), Ozempic (diabetes indication, same molecule), Rybelsus (oral tablet form).
• Class: GLP-1 receptor agonist — glucagon-like peptide-1, the gut hormone that signals satiety to your brain after meals.
• Dosing: Injection 0.25 → 2.4mg weekly. Oral 3 → 7 → 14mg daily.
• Trial efficacy: -15% body weight at 2.4mg/wk over 68 weeks (STEP-1).
• Patent status: Injectable patent expired in India March 2026 (per CDSCO public approval listings). US patent runs to 2031 (Novo Nordisk Composition of Matter). The Indian generic launch happens because Indian patent law diverged after WTO transition periods — separate jurisdiction, separate patent term.
• Format choice (oral vs injection): Same molecule, two delivery formats with different bioavailability and dose-ceiling profiles. Detail at Rybelsus vs Wegovy — oral vs injection for the same molecule.

Tirzepatide

• Brand names: Mounjaro (diabetes), Zepbound (weight loss).
• Class: Dual GIP / GLP-1 receptor agonist. Hits two gut hormone receptors instead of one.
• Dosing: Injection 2.5 → 15mg weekly.
• Trial efficacy: -20.9% body weight at 15mg/wk over 72 weeks (SURMOUNT-1).
• Patent status: Eli Lilly composition patents run to early 2030s in most jurisdictions. Indian generic launch — not yet, no public DCGI approval as of April 2026.
• Practical note: The strongest weight-loss molecule in the class. Also the one with no generic lane — and not in our routing lane, full stop. If your decision is sema-vs-tirz on efficacy alone, the head-to-head numbers and the access tradeoffs are at Tirzepatide vs semaglutide — the honest comparison.

Liraglutide

• Brand names: Saxenda (weight loss), Victoza (diabetes).
• Class: GLP-1 receptor agonist, daily injection (older drug, shorter half-life).
• Dosing: Injection 0.6 → 3.0mg daily.
• Trial efficacy: -5 to -8% body weight at 3.0mg/day (SCALE trials, 2015).
• Patent status: Expired 2024 in many jurisdictions. Some Indian liraglutide brands exist domestically; export-grade generic supply for personal-import is not yet established.
• Practical note: Largely superseded by semaglutide. Daily injections lost the format war to weekly. Smaller weight loss effect for more needles.

Dulaglutide (Trulicity)

• Diabetes indication only. Not approved for obesity. Roughly 3-5% weight loss as a side effect at diabetes doses. Skip unless your doctor specifically wants this for A1c reasons.

Cagrilintide-semaglutide (CagriSema), retatrutide, orforglipron

• Pipeline drugs. Not approved as of April 2026. CagriSema and retatrutide are in late-stage Eli Lilly / Novo Nordisk trials with weight loss numbers approaching -25%. Orforglipron is an oral non-peptide GLP-1 that may reach market 2027-2028. The class is still moving.

For most people in 2026, the choice is semaglutide (the one with a generic lane already open) or tirzepatide (the strongest, but only via brand or US compounded supply).

3. The cost lanes, all six of them

The Wegovy retail list price ($1,200-1,800/mo) is the price you see in the headlines, but it isn't the only number. There are six distinct cost lanes for the same molecule, and most patients have only seen one or two of them.

The lanes are not equivalent. They differ on speed (lane 6 is 2 weeks; lane 1-3 are days), on consult depth (lane 1 has your actual doctor; lane 6 is no consult), on dose-strength availability (lane 6 runs lumpier), and on how stable they are if your insurance changes (lane 1 dies if insurance stops, lane 2-6 don't).

The cost spread is real and it is also accurate. We've covered the markup breakdown of lane 1 in Wegovy retails at $1,800. Sun Pharma's generic launched at $80. Where the catch is. — short version: roughly 1% of the brand list price is the molecule. The other 99% is the patent moat plus the PBM-insurance-wholesaler margin chain plus DTC marketing.

The compounded semaglutide lane (lane 5) deserves an asterisk. Tirzepatide came off the FDA shortage list October 2024; semaglutide followed February 21, 2025 (with grace periods through April-May 2025). The legal exemption that allowed mass-market compounding is mostly closed. Most compounders pivoted, some are operating under personalized-prescribing rules that look more like lane 4 in practice. The "$200/mo from a Florida compounder" you may have seen on Reddit a year ago is not the same product on the same legal footing today.

Mini decision tree (the 30-second version)

The full version is in Section 9. Quick orientation while you're still reading:

• Scenario A — Insured, BMI ≥30 (or ≥27 + comorbidity), haven't started. Push for prior authorization first. The $25-50 covered copay is the cheapest legitimate lane. Cash-pay only if denied.
• Scenario B — Cash-pay, considering starting. NovoCare Direct ($149-399/mo) → telehealth (Hims/Ro, $149-299/mo) → compounded ($200-400) → personal-import ($80-150). Get baseline labs and a DEXA before any of them.
• Scenario C — On it 6+ months, considering stopping for cost. Don't collapse "stop the drug" with "stop paying $1,400." Price every cheaper lane before zero. Taper over 2-3 months if you do stop.

Sections 4-8 are the depth — side effects, dose ladder, the stopping question, and the lane-6 mechanics. Section 9 is the full decision tree.

4. Side effects, separated from internet folklore

If you just need cost lanes and what to do this week, skip to Section 9. Sections 4-5 are the side-effect profile and dose ladder — most useful once you've decided to start.

The GLP-1 side effect profile has roughly four real items, and a few internet myths.

Real side effect 1: GI distress (the big one)

Roughly 30-70% of users report nausea, vomiting, diarrhea, or constipation at some point during titration. Severity is dose-dependent. Most resolves over 4-8 weeks as you stay at a given dose, then re-emerges briefly when you titrate up.

This is the side effect that drives discontinuation in the first 90 days. Practical management:

• Eat smaller meals. The drug is slowing gastric emptying — overfilling a slow-emptying stomach causes vomiting.
• Cut fat content sharply. High-fat meals exacerbate nausea more than carbs do.
• Hydrate hard. Dehydration from vomiting / diarrhea is the actual medical risk.
• Stay at each dose 4 weeks before titrating up. The 4-week step is in the label, not optional.
• Anti-nausea (ondansetron 4-8mg) is reasonable for the first 1-2 weeks of each new dose if you can get a prescription.

Detail on managing the nausea phase: GI side effects on GLP-1 — what's normal vs. stop. For oral semaglutide specifically, the SNAC absorption protocol changes the calculus — see Rybelsus GI side effects: the SNAC protocol that doubles or breaks the dose.

Real side effect 2: Gallbladder issues

Rapid weight loss of any kind — bariatric surgery, very low calorie diets, GLP-1 — increases gallstone risk. STEP-1 reported gallbladder events in ~2.6% of semaglutide patients vs. ~1.2% on placebo. Cholecystectomy (gallbladder removal) showed up at ~0.6% over 68 weeks.

Sign to take seriously: persistent right-upper-quadrant pain, especially after meals. Fatty meals trigger it. Don't push through it.

Real side effect 3: Pancreatitis (rare, but real)

Acute pancreatitis is a labeled GLP-1 side effect, occurring in roughly 0.1-0.2% of patients across the trial population. The signal is severe, persistent abdominal pain radiating to the back, with elevated lipase/amylase on labs. Stop the drug and go to an ER if this happens. Don't titrate up if you've ever had pancreatitis.

Real side effect 4: Muscle / lean mass loss

Of the 15% weight lost on semaglutide, roughly 30-40% is lean mass — muscle and bone density — not fat. This is a known finding from STEP-1 DEXA substudy data and from clinical practice.

Mitigation:

• Resistance training 2-3× per week. Not optional.
• Protein 1.2-1.6g per kg of body weight per day.
• Consider a baseline DEXA scan now to see what you started with.

Internet myths, separated

• Thyroid cancer (medullary): Rodent signal in early studies, used to put a black box warning on the label. Human data over a decade of use has not confirmed a thyroid cancer association. The MTC contraindication remains for people with personal/family history of medullary thyroid cancer or MEN2 — that's a real flag, not for the general population.
• "Ozempic face": The hollow-cheek look is rapid weight loss, not a drug-specific effect. Same look from any rapid weight loss method.
• Suicidal ideation: EMA reviewed this in 2023-2024 and FDA followed in 2024. No causal signal in pooled data. Specific cases exist but the rate is not above background.
• Hair loss: Reported. Likely related to rapid weight loss / caloric deficit / micronutrient stress, not drug-specific. Resolves with weight stabilization.
• "Resets your metabolism" / "trains your gut": No. The drug occupies receptor sites. When the drug leaves, the receptor sites return to baseline signaling. No retraining is happening.

5. The titration ladder

The dosing schedule for semaglutide weight-loss indication is:

For tirzepatide (Mounjaro/Zepbound):

Key points the prescription summary doesn't always make plain:

• The 4-week-per-step rule is a tolerance ramp, not a strict requirement. If you tolerate a step well, the next step is fine at week 4. If you don't tolerate it, hold at the current dose another 4 weeks. Telehealth clinics that push you up the ladder on a fixed calendar regardless of tolerance are running their schedule, not yours.
• You do not have to reach 2.4mg. The dose-response curve flattens above 1.0-1.7mg for many people. If you're hitting your target loss at 1mg, staying at 1mg is fine. The 2.4mg max is the dose with the strongest effect, but also the strongest GI side effect profile.
• You do not have to stay at 2.4mg. STEP-4 (Rubino 2021, JAMA) shows that staying at 2.4mg maintains the loss. STEP-4 does not show that lower-dose maintenance fails — it just didn't study lower-dose maintenance. Many practitioners taper to 1mg or 1.7mg for maintenance. Trial data on this is thin; clinical experience is broad.
• Restarting after a gap restarts the titration. If you've been off the drug for more than 2-3 weeks, you go back to 0.25mg, not back to your old dose. The GI tolerance you'd built decays.

The Wegovy injection ladder has its own logic — why 0.25mg is sub-therapeutic by design and what dropping a step costs you in dropout risk: Wegovy 0.25 → 2.4mg ladder — the GI habituation runway. For the Rybelsus oral ladder (3 → 7 → 14mg) and why most oral users plateau at 7mg without realizing 14mg is the actual dose: Rybelsus 3-7-14mg titration — what the prescriber didn't push you to.

6. The stopping question

This is where most people make the wrong decision, and the wrong decision is shaped by the cost lane they're in.

The Wilding 2022 STEP-1 extension followed 327 semaglutide responders for one year off the drug. They regained ~67% of the weight loss in 12 months. The lifestyle interventions continued. Only the drug stopped.

Translation: GLP-1 is not a course of antibiotics. It's not LASIK. It's much closer to blood pressure medication or glasses. The drug works while you're taking it. When you stop, the effect goes.

The full 67% number deserves a deeper look — covered in Most Ozempic users gain 67% of the weight back within a year of stopping. — but the headline is: plan for indefinite use, not 6 months.

When stopping is the right call:

• Side effects you can't tolerate at any dose. Pancreatitis signal, severe gallbladder symptoms, persistent vomiting that won't resolve. These are stop-and-reassess.
• A1c normalized off other diabetes meds, BP off meds, lipids in range, and you've been maintaining loss at the lowest dose for 12+ months. ~10% of STEP-1 responders held loss off-drug. It exists, it's just not the modal outcome.
• You moved into a different chronic plan (bariatric surgery, structured medical weight loss program with different mechanism).

When stopping is the cost calculation in disguise:

• "I can't afford $1,400/mo Wegovy retail anymore." This is not a clinical decision; it's a price decision. Before you taper to zero, price NovoCare Direct ($149-399/mo: Wegovy Pill $149, Wegovy Pen $199 promo or $349 standard, Wegovy HD 7.2mg $399), telehealth (lane 3, $149-299/mo), or LiberaCure-routed generic ($80-150/mo). The "I want to be off the drug" decision and the "I can't pay $1,400" decision are not the same decision, and they shouldn't get collapsed.
• "I'm at goal weight, I'll just maintain with willpower." The trial data does not support this for most people. ~67% regain in 12 months on top of structured lifestyle support. Without the structured lifestyle support, the regain is faster.

7. The personal-import lane: what we route, what we don't, and what's missing

This is the part that benefits from radical transparency, because it's the lane we're in.

What we route

Semaglutide oral (tablets): Two product lines.

• Rybelsus brand (Novo Nordisk India). Same molecule, same dose tiers as US Rybelsus, lower price reflecting Indian domestic market.
• Sembolic (Torrent Pharmaceuticals). Generic semaglutide oral, 3mg / 7mg / 14mg tablets, the full ladder. Indian generic launch March 2026.

Semaglutide injection (pens): Several product lines from different Indian export specialists.

• Noveltreat (Sun Pharma) — full ladder 0.25 / 0.5 / 1.0 / 1.7 / 2.4mg pens.
• Obeda (Dr. Reddy's) — 2mg and 4mg pen formats.
• Semasize (Alkem) — full ladder 0.25 to 2.4mg pens.
• Sematrinity (Sun Pharma) — 0.5mg and 1mg pens.

Catalog availability shifts week to week — generic pen format launched March 2026, demand is volatile, and not every dose tier is stocked simultaneously. We route what's stocked. Cost runs $80-150/month depending on dose tier and brand. The four-pen teardown — ladder completeness, manufacturer, format, price — is at Wegovy generic pens compared — Noveltreat / Obeda / Semasize / Sematrinity.

Other weight-management adjuncts: Metformin (Bigomet, Glycomet SR), topiramate (Topaheal), orlistat (multiple brands). Not GLP-1, but commonly stacked or used as alternatives. The orlistat lane has its own niche role — six brands, ~30% fat-blocking mechanism, why most users quit by month 3: Xenical and the six orlistat generics — niche role in the GLP-1 era. Metformin's longevity-clinic markup story is separate from its weight role: Metformin and the $300-400/mo longevity clinic protocol.

What we don't route

Tirzepatide (Mounjaro/Zepbound). Eli Lilly composition patent runs through early 2030s in most jurisdictions, including India. No DCGI approval for an Indian generic tirzepatide as of April 2026. If you need tirzepatide specifically, your lanes are: brand at retail (lane 1, $1,000-1,200/mo), big telehealth (lane 3, ~$299/mo for Zepbound brand), or compounded tirzepatide via a US 503A pharmacy under personalized-prescribing rules (lane 5, $200-400/mo, narrower legal footing post-shortage).

Liraglutide (Saxenda). Saxenda exists as a daily-injection precursor to semaglutide. Indian generic supply isn't established for export at the personal-import scale. Not in our routing lane. If liraglutide is your specific molecule, lane 1-3 are the realistic options.

Dulaglutide (Trulicity). Diabetes drug, not weight-loss-indicated, and not in our routing lane regardless.

This is the honest limitation of the personal-import lane in April 2026: it is currently a semaglutide-only lane. If your prescriber has put you on tirzepatide for a clinical reason — better weight loss numbers, better tolerance for some patients, dual GIP/GLP-1 mechanism — the cost gap to brand or compounded is what it is.

What lane 6 actually costs (the breakdown)

For reference on what the $80-150 actually covers on our end: payment is crypto-only (BTC, USDT TRC-20, LTC, XMR, ETH via NOWPayments). That's the operational choice that lets the markup tier sit where it does — card-network fees and personal-import-processor premiums get skipped. Lead time is 2 weeks standard, 2-4 weeks with customs variance, tracking active 24-48h after dispatch.

Cold-chain (2-8°C) handling for pens is the supplier's responsibility end-to-end. We don't warehouse pens; the Indian pharmacy ships insulated direct to you. Oral semaglutide (Sembolic / Rybelsus tablets) is shelf-stable and ships in standard packaging.

If a package doesn't land: LiberaCure reships once free if tracking shows lost in transit. Second reship also free. Crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]) — no live chat, no phone. Crypto means no chargeback, so this explicit reship-then-refund is our equivalent of dispute resolution.

Personal-import legal frameworks (US / UK / AU / EU)

Personal-import is a country-specific legal lane, not a universal rule. Quick summary of the four major Anglo-EU jurisdictions as of April 2026:

• United States — FDA Personal Importation Policy. Up to a 90-day supply for personal use, prescription drug, no commercial intent, declared at customs. Not formally "approved" — the FDA exercises enforcement discretion. Semaglutide for weight loss falls inside the practice. Schedule II-IV controlled substances do not.
• United Kingdom — MHRA personal-import. Up to a 12-week (84-day) supply for personal use, the medicine must be for the importer (not for resale or supply to others). MHRA tolerates personal-import of prescription medicines including GLP-1s; the lane sits in the same enforcement-discretion frame as the US.
• Australia — TGA Personal Importation Scheme. 3-month supply per import, total stock on hand should not exceed 15 months' worth, the medicine must not be on the prohibited list (Schedule 4 substances generally allowed for personal use, Schedule 8 prohibited). Semaglutide is Schedule 4 — personal-import is permitted under the standard scheme. Some states have additional notification requirements; check the TGA scheme page before ordering.
• European Union — fragmented. Personal-import legality is set at the member-state level. Germany, France, Italy, Spain each have separate rules; some allow personal-import of EMA-approved medicines for personal use, some require a prescription presented at customs, some prohibit it outright. There is no single EU-wide personal-import lane. Check your specific country's medicines regulator before assuming the US/UK/AU framework applies.

The framework full text and the country-by-country breakdown is at /honestly.

8. Compounded vs. lane 6: the lane comparison most-asked

Compounded semaglutide from a US 503A pharmacy and LiberaCure-routed generic semaglutide are two different lanes that get conflated in Reddit threads. They are not the same lane.

Both have legitimate operating models. The compounded lane is closer to the "feels like a US doctor wrote this" experience and currently sits in a narrower legal frame than it did in 2023. The personal-import lane is cheaper, slower, no consult, prefilled-pen format, and stocks vary.

If consult depth and US clinical handoff are what you want, lane 5 is closer to that. If raw cost is the binding constraint, lane 6 is meaningfully cheaper. They are not substitutes for the same person; they are different bundles.

We have a deeper comparison at NovoCare vs telehealth vs personal-import — picking the right semaglutide lane and The 2025 compounding crackdown — what happened when the FDA shortage ended.

9. Decision tree: what to do this week

Three scenarios. Pick the one that matches you.

Scenario A: "I'm insured, BMI ≥30 (or ≥27 with comorbidity), haven't started yet."

1. Push for prior authorization on Wegovy or Zepbound through your doctor. Worth 4-12 weeks of paperwork. The covered cost ($25-50 copay/mo) is the cheapest legitimate lane if you have it.
2. If denied, escalate to formulary exception. Your doctor cites STEP-1 (semaglutide) or SURMOUNT-1 (tirzepatide) as the rationale. Many denials reverse at this stage.
3. If still denied, you're in the cash-pay path — read Scenario B.

Scenario B: "I'm cash-pay, no insurance coverage, considering starting."

1. First lane to check: NovoCare Direct, $149-399/month. Most cash-payers don't know this exists because it's not what gets advertised. Wegovy Pill is $149/mo, Wegovy Pen is $199/mo on the current promo or $349/mo standard, Wegovy HD 7.2mg is $399/mo. Wegovy / Ozempic only. If you can absorb that range, this is the lowest-friction "real US prescription with brand pen" option.
2. If NovoCare Direct is still too much, the meaningful cheaper lanes are: Hims weight loss / Ro Body telehealth (lane 3, ~$149-299/mo for brand pen at telehealth markup), compounded sema via US 503A (lane 5, $200-400/mo, narrower legal frame post-shortage), or LiberaCure-routed generic (lane 6, $80-150/mo, 2-week ship from licensed Indian pharmacy).
3. Before ordering anything, get baseline labs. A1c, lipid panel, comprehensive metabolic panel. If you're starting GLP-1, you want to know your starting cardiometabolic markers so you can see what changes.
4. Get a baseline DEXA or bioimpedance scan. Lean mass loss is real on GLP-1. Knowing your starting fat-vs-muscle composition makes the loss interpretable.
5. Plan the maintenance dose now, not month 9. Don't start without knowing what your monthly cost looks like at month 18 if you're still on it. The drug is chronic. The budget should be too.

Scenario C: "I've been on it 6+ months, considering stopping for cost reasons."

1. Don't collapse "stop the drug" with "stop paying $1,400." They're separate decisions. Price every cheaper lane before zero.
2. If you do taper, taper down through doses (1.7 → 1.0 → 0.5 → 0.25 → off) over 2-3 months. Cold-stop from 2.4mg sets up the strongest regain trajectory.
3. If you stay on at lower-dose maintenance (1mg/week or 1.7mg/week instead of 2.4mg), know the trial data is thin. STEP-4 studied "stay on full dose vs stop," not gradual taper. Lower-dose maintenance is clinical practice without trial backing — discuss with whoever's prescribing.
4. Track weight weekly post-stop. The regain trajectory in the trial showed steady accumulation, not a cliff. If you're regaining at >1 lb/week, you have time to make a different decision.

10. The science is still moving

Three things to watch over 2026-2027:

• CagriSema (cagrilintide-semaglutide combo). Phase 3 results expected 2026. If trial data holds, weight loss numbers approach -25%. Novo Nordisk pipeline.
• Retatrutide (Lilly triple-agonist). Triple receptor — GLP-1, GIP, glucagon. Phase 3 ongoing. Phase 2 reported -24% body weight at 48 weeks.
• Orforglipron (Lilly oral non-peptide GLP-1). Phase 3 reading out. Targets 2027 launch. Oral, non-peptide (not bioequivalent to Rybelsus oral semaglutide), potentially much cheaper to manufacture.

The class will likely look quite different in 2028 than it does today. Today's decisions don't have to assume today's drugs are the final answer.

A note on bias.

We route semaglutide orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Sembolic (by Torrent Pharmaceuticals) for oral and Noveltreat (by Sun Pharma) for injection are two of the products we route most often, alongside generic semaglutide pens from other global pharma giants (Alkem's Semasize, Dr. Reddy's Obeda, where stocked). We do not route the brand-name Novo Nordisk pens or Rybelsus tablets themselves. We do not route tirzepatide, liraglutide, or dulaglutide — tirzepatide isn't in the Indian generic export pipeline at all (no DCGI approval as of April 2026), and liraglutide/dulaglutide aren't at a scale that supports a personal-import lane.

So we have a financial reason to want this article to lead you toward "give it a try" — and to keep filling.

Read this with that in mind. The protocol above is what I'd tell a friend, not what maximizes reorder rate. The lane comparison is honest. Lane 6 is cheap; it's also the slowest, has no consult, and currently doesn't carry the strongest weight-loss molecule in the class.

Sources:

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021;384:989-1002. PMID 33567185
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470
• Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP-4). JAMA 2021;325(14):1414-1425.
• Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2). Lancet 2021;397:971-984.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med 2015;373:11-22.
• ADA / EASD 2022 consensus report, Management of Hyperglycemia in Type 2 Diabetes. Diabetes Care 2022;45(11):2753-2786.
• Novo Nordisk Wegovy SmPC and US prescribing information (current revision); NovoCare Direct self-pay program (Wegovy Pill $149/mo, Wegovy Pen $199 promo or $349 standard, Wegovy HD 7.2mg $399/mo, accessed April 2026).
• Eli Lilly Mounjaro and Zepbound prescribing information (current revision).
• FDA Drug Shortages Database — tirzepatide resolved October 2024; semaglutide resolved February 21, 2025 (503A grace through April 22, 2025; 503B through May 22, 2025).
• DCGI / CDSCO public approval listings — Sun Pharma Noveltreat, Torrent Sembolic, Dr. Reddy's Obeda, Alkem Semasize (semaglutide generics, India launches Q1 2026).
• Hims weight loss pricing ($149-299/mo across Wegovy Pill / Wegovy Pen / Ozempic Pen / Zepbound Vial; Mounjaro/Zepbound brand $1,899/mo; membership $39 first / $149 thereafter), accessed April 2026.
• IBEF (India Brand Equity Foundation), Indian Pharmaceutical Industry Report 2024.

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.